RosettaCommons/UTexasAptamer huggingface dataset:
Aptamer: Tr-8
Target: Soluble Interleukin 2 Receptor α (CD25)
Type of nucleic acid: ssRNA
Sequence: 5'GGGAGGACGAUGCGGGCCGUUGUUGUGUGCCGCCCCAGACGACUCGCCCGA3'
Sequence length: 51
GC content: 0.7058823529411765
Affinity: Kd: 35.7 ± 1.56 nM
Pool type: 5'-GGGAGGACGAUGCGG-N20-CAGACGACUCGCCCGA-3'
Pool random region: 20
Binding buffer/conditions: HEPES-buffered saline, pH 7.5 with 2 mmol/L CaCl2) containing BSA (0.1 mg/mL) and tRNA (0.1 mg/mL)
Divalent salt: CaCl
Buffer type: Other Buffers
pH: 7.5
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " serve as a high-throughput biomarker platform to quantify the fraction of receptors occupied by a ligand. In summary, this report described an assay platform, designated the LIRECAP assay, that is based on pairs of RNA aptamers that bind differentially based on the presence or absence of ligand. Such assays can be used to quantify the fraction of receptors occupied by ligand in a variety of biospecimens. Here, the IL2-CD25 complex as a biomarker for lymphoma was used in these proof-of-principle studies. However, a similar approach could be applied to a broad variety of molecular complexes and disease conditions."
Reference (2019, Cancer Immunol Res ): Veeramani, S., Blackwell, S. E., Thiel, W. H., Yang, Z. Z., Ansell, S. M., Giangrande, P. H., & Weiner, G. J. (2019). An RNA Aptamer-Based Biomarker Platform Demonstrates High Soluble CD25 Occupancy by IL2 in the Serum of Follicular Lymphoma Patients. Cancer immunology research, 7(9), 1511–1522. https://doi.org/10.1158/2326-6066.CIR-18-0821
Aptamer: Tr-11
Target: Soluble Interleukin 2 Receptor α (CD25)
Type of nucleic acid: ssRNA
Sequence: 5'GGGAGGACGAUGCGGAUUCUGGUUACUGGCCGCCCCAGACGACUCGCCCGA3'
Sequence length: 51
GC content: 0.6666666666666666
Affinity: Kd: 46.1 ± 1.76 nM
Pool type: 5'-GGGAGGACGAUGCGG-N20-CAGACGACUCGCCCGA-3'
Pool random region: 20
Binding buffer/conditions: HEPES-buffered saline, pH 7.5 with 2 mmol/L CaCl2) containing BSA (0.1 mg/mL) and tRNA (0.1 mg/mL)
Divalent salt: CaCl
Buffer type: Other Buffers
pH: 7.5
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " serve as a high-throughput biomarker platform to quantify the fraction of receptors occupied by a ligand. In summary, this report described an assay platform, designated the LIRECAP assay, that is based on pairs of RNA aptamers that bind differentially based on the presence or absence of ligand. Such assays can be used to quantify the fraction of receptors occupied by ligand in a variety of biospecimens. Here, the IL2-CD25 complex as a biomarker for lymphoma was used in these proof-of-principle studies. However, a similar approach could be applied to a broad variety of molecular complexes and disease conditions."
Reference (2019, Cancer Immunol Res ): Veeramani, S., Blackwell, S. E., Thiel, W. H., Yang, Z. Z., Ansell, S. M., Giangrande, P. H., & Weiner, G. J. (2019). An RNA Aptamer-Based Biomarker Platform Demonstrates High Soluble CD25 Occupancy by IL2 in the Serum of Follicular Lymphoma Patients. Cancer immunology research, 7(9), 1511–1522. https://doi.org/10.1158/2326-6066.CIR-18-0821
Aptamer: MS10
Target: Mycobacterium tuberculosis (Mtb) Malate synthaseMS
Type of nucleic acid: ssDNA
Sequence: 5'GTCTTGACTAGTTACGCCGGTGTGTTGACTGAGGGGGTGGGGTGGGTGGTGGTGGATATAGCTCATTCAGTTGGCGCCTC3'
Sequence length: 80
GC content: 0.575
Affinity: Kd: 12 nM
Pool type: 5'-GTCTTGACTAGTTACGCC-N44-TCATTCAGTTGGCGCCTC-3'
Pool random region: 44
Binding buffer/conditions: 10 mM Tris [pH 7.5], 10 mM MgCl2, 50 mM KCl, 25 mM NaCl)
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.5
Molecular weight of target: Not reported
Post-SELEX modifications: Not appilcable
Application as quoted in the referenced paper: Detection: " The theranostic potential of the best-performing and optimized G4-forming aptamer, MS10-Trunc, was established through binding studies using ALISA and SPR, enzyme inhibition assay, binding and inhibition of Mtb invasion into host cells, and demonstrating its diagnostic utility in TBM. We anticipate that MS10-Trunc holds promise for the development of a novel MS-targeted theranostics approach against Mtb and may complement the existing diagnostic and therapeutic modalities in the near future."
Additional information: Pool was obtained from a cited paper: Dhiman, A., Haldar, S., Mishra, S. K., Sharma, N., Bansal, A., Ahmad, Y., Kumar, A., Sharma, T. K., & Tyagi, J. S. (2018). Generation and application of DNA aptamers against HspX for accurate diagnosis of tuberculous meningitis. Tuberculosis (Edinburgh, Scotland), 112, 27–36. https://doi.org/10.1016/j.tube.2018.07.004
Reference (2019, Mol Ther Nucleic Acids ): Dhiman, A., Kumar, C., Mishra, S. K., Sikri, K., Datta, I., Sharma, P., Singh, T. P., Haldar, S., Sharma, N., Bansal, A., Ahmad, Y., Kumar, A., Sharma, T. K., & Tyagi, J. S. (2019). Theranostic Application of a Novel G-Quadruplex-Forming DNA Aptamer Targeting Malate Synthase of Mycobacterium tuberculosis. Molecular therapy. Nucleic acids, 18, 661–672. https://doi.org/10.1016/j.omtn.2019.09.026
Aptamer: EPCAM-APT-01
Target: Epithelial cell adhesion molecule (EpCAM)
Type of nucleic acid: ssDNA
Sequence: 5′CTCCTCTGACTGTAACCACGACACGCACAAATGTCAGTGTACCGCACTCGCACATTCTTAGCATAGGTAGTCCAGAAGCC3′
Sequence length: 80
GC content: 0.5125
Affinity: Kd: 25 nM
Pool type: 5′-CTCCTCTGACTGTAACCACG-N40-GCATAGGTAGTCCAGAAGCC-3′
Pool random region: 40
Binding buffer/conditions: Dulbecco's phosphate buffered saline (DPBS, Sigma-Aldrich, St. Louis, MO, USA)
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: 40 kDa
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " The developed aptamer clones, EPCAM-APT-01 and EPCAM-APT-02, may be further used for EpCAM detection in real clinical samples in most human adenocarcinomas and it is a marker for cancer stem cells in several solid cancers. However, before using EpCAM aptamers for clinical diagnostics, it is necessary to study epitope structures of EpCAM-aptamer complexes by affinity mass spectrometry, protein X-ray crystallography, and small-angle X-ray scattering"
Reference (2019, Cancers (Basel) ): Zamay, G. S., Kolovskaya, O. S., Ivanchenko, T. I., Zamay, T. N., Veprintsev, D. V., Grigorieva, V. L., Garanzha, I. I., Krat, A. V., Glazyrin, Y. E., Gargaun, A., Lapin, I. N., Svetlichnyi, V. A., Berezovski, M. V., & Kichkailo, A. S. (2019). Development of DNA Aptamers to Native EpCAM for Isolation of Lung Circulating Tumor Cells from Human Blood. Cancers, 11(3), 351. https://doi.org/10.3390/cancers11030351
Aptamer: EPCAM-APT-02
Target: Epithelial cell adhesion molecule (EpCAM)
Type of nucleic acid: ssDNA
Sequence: 5′CTCCTCTGACTGTAACCACGGTGCGCGTACCACCATGTGTACACACTGCATGTTTGGTTAGCATAGGTAGTCCAGAAGCC3′
Sequence length: 80
GC content: 0.525
Affinity: Kd: 15 nM
Pool type: 5′-CTCCTCTGACTGTAACCACG-N40-GCATAGGTAGTCCAGAAGCC-3′
Pool random region: 40
Binding buffer/conditions: Dulbecco's phosphate buffered saline (DPBS, Sigma-Aldrich, St. Louis, MO, USA)
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: 40 kDa
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " The developed aptamer clones, EPCAM-APT-01 and EPCAM-APT-02, may be further used for EpCAM detection in real clinical samples in most human adenocarcinomas and it is a marker for cancer stem cells in several solid cancers. However, before using EpCAM aptamers for clinical diagnostics, it is necessary to study epitope structures of EpCAM-aptamer complexes by affinity mass spectrometry, protein X-ray crystallography, and small-angle X-ray scattering"
Reference (2019, Cancers (Basel) ): Zamay, G. S., Kolovskaya, O. S., Ivanchenko, T. I., Zamay, T. N., Veprintsev, D. V., Grigorieva, V. L., Garanzha, I. I., Krat, A. V., Glazyrin, Y. E., Gargaun, A., Lapin, I. N., Svetlichnyi, V. A., Berezovski, M. V., & Kichkailo, A. S. (2019). Development of DNA Aptamers to Native EpCAM for Isolation of Lung Circulating Tumor Cells from Human Blood. Cancers, 11(3), 351. https://doi.org/10.3390/cancers11030351
Aptamer: Az9
Target: Azlocillin
Type of nucleic acid: ssDNA
Sequence: 5′ATACCAGCTTATTCAATTCAGGAAGACAACTCCGACTAGAATTGATAATCAAGAATTCGTCTGGGGGGAATGTGCGAGATAGTAAGTGCAATCT3′
Sequence length: 94
GC content: 0.4042553191489361
Affinity: Kd: 55 nM
Pool type: 5′-ATACCAGCTTATTCAATT-N60-AGATAGTAAGTGCAATCT-3′
Pool random region: 60
Binding buffer/conditions: 50 mM Tris, pH 7.5, 150 mM NaCl and 2 mM MgCl2
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.5
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Biosensor and Detection: " The performance of the developed aptasensor was challenged by directly measuring azlocillin in spiked tap and wastewater samples showing excellent recovery percentages. Thus, the proposed platform offers several advantages over current methods including the lower cost and higher stability of the aptamer as well as the ease of use of the electrochemical transducers and their availability as hand-held devices. These features make our aptasensor of great value for the detection of emerging environmental contaminates."
Reference (2020, Anal Chim Acta ): Chinnappan, R., Eissa, S., Alotaibi, A., Siddiqua, A., Alsager, O. A., & Zourob, M. (2020). In vitro selection of DNA aptamers and their integration in a competitive voltammetric biosensor for azlocillin determination in waste water. Analytica Chimica Acta, 1101, 149–156. https://doi.org/10.1016/j.aca.2019.12.023
Aptamer: aptamer 31
Target: Di(2-ethylhexyl) phthalate (DEHP)
Type of nucleic acid: ssDNA
Sequence: 5′ATTGGCACTCCACGCATAGGACGCATAGGGTGCGACCACATACGCCCCATGTATGTCCCTTGGTTGTGCCCTATGCGTCCTATGCGTGCTACCGTGAA3′
Sequence length: 98
GC content: 0.5612244897959183
Affinity: Kd: 2.26 ± 0.06 nM
Pool type: 5′-ATTGGCACTCCACGCATAGG-N40-CCTATGCGTGCTACCGTGAA-3′
Pool random region: 40
Binding buffer/conditions: DPBS buffer (0.1 g CaCl2, 0.2 g KCl, 0.2 g KH2PO4, 0.1 g MgCl2.6H2O, 8 g NaCl, and 1.15 g Na2HPO4; 1 L, pH 7.5)
Divalent salt: MgCl/CaCl
Buffer type: PBS/phosphate buffers
pH: 7.5
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Biosensor and Detection: " In this study, a novel aptamer specific for DEHP was selected, and a direct DEHP detection method based on an electrochemical aptasensor with ultrasensitivity was developed for low-cost, rapid, and sensitive detection. Most importantly, the rapid selection and identification strategy proposed in this study decreased the cost, complexity, and difficulty of the experiment. As a universal technical method, it can be used for the selection and identification of other aptamers specific for small molecules."
Reference (2020, Molecules ): Lu, Q., Liu, X., Hou, J., Yuan, Q., Li, Y., & Chen, S. (2020). Selection of Aptamers Specific for DEHP Based on ssDNA Library Immobilized SELEX and Development of Electrochemical Impedance Spectroscopy Aptasensor. Molecules, 25(3), 747. https://doi.org/10.3390/molecules25030747
Aptamer: T1–T4 dimer
Target: Anti-human tumor necrosis factor alpha (anti‐hTNF‐α)
Type of nucleic acid: ssDNA
Sequence: 5′GCTGTGTGACTCCTGCAATCCGATCGGTATATCCGTCGGATTTTTTTTTTGGTCACTGCATGTGACCGCAGCTGTATCTTGTCTCC3′
Sequence length: 86
GC content: 0.4883720930232558
Affinity: Kd: 67nM
Pool type: 5′‐GCTGTGTGACTCCTGCAA‐N42‐GCAGCTGTATCTTGTCTCC‐3′
Pool random region: 42
Binding buffer/conditions: Binding buffer (50 mM Tris–HCl, 5 mM KCl, 100 mM NaCl, 1 mM MgCl2, pH 7.4)
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.4
Molecular weight of target: 15 kDa
Post-SELEX modifications: The t1 and t4 were linked with 10 oligos (dt) and created dimer aptamer
Application as quoted in the referenced paper: Diagnostic and Therapeutic: " The human tumor necrosis factor α (hTNF-α) is an important pro-inflammatory cytokine which plays critical roles in inflammatory diseases such as rheumatoid arthritis (RA). The anti-TNF-α proteins can reduce symptoms of RA. With regard to the several limitations of anti-TNF-α proteins therapies including immunogenicity, side effects, and cost-intensive, a new designed anti-hTNF-α dimer aptamer could be considered as a potential therapeutic and/or diagnostic agent for hTNF-α-related disorders."
Reference (2020, Biotechnol Prog ): Mashayekhi, K., Ganji, A., & Sankian, M. (2020). Designing a new dimerized anti human TNF‐α aptamer with blocking activity. Biotechnology Progress, 36(4). https://doi.org/10.1002/btpr.2969
Aptamer: aptamer 1
Target: Crystalline hydroxyapatite (Ca10(PO4)6(OH)2; HAP)
Type of nucleic acid: ssDNA
Sequence: 5'TCCCACGCATTCTCCACATCCAGGGCGCTACGGTATGTGTTGGGTCTGGCGTAGGGCTGGCTTTCTGTCCTTCCGTCACAA3'
Sequence length: 81
GC content: 0.5802469135802469
Affinity: Ka: 3.0 + 0.9 × 10^6 M−1
Pool type: 5'-TCCCACGCATTCTCCACATC-N40-TTTCTGTCCTTCCGTCACAA-3'
Pool random region: 40
Binding buffer/conditions: Tris-Mg buffer( 10 mM trizma hydrochloride, 1.0 mM magnesium chloride, pH 7.4)
Buffer type: Tris Buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Research: " The fluorescently-functionalized aptamer was demonstrated to specifically label HAP in a surface binding experiment and suggests the usefulness of this selected aptamer in biomedical or biotechnology fields where the labeling of specific calcium phosphate materials is required. We anticipate that fluorescently-labeled or gold nanoparticle-labeled aptamers would have potential as affinity and labeling reagents in light microscopy or electron microscopy where differentiation between crystalline and amorphous material would be beneficial."
Additional information: In this work, we present an affinity-based selection attempting to identify DNA aptamers with selectivity and enhanced kinetic binding to hydroxyapatite (Ca10(PO4)6(OH)2; HAP). HAP is an important biomaterial with medical implications in bone and enamel regeneration. Aptamer 1 having a Ka of 3.0 + 0.9 × 106 M−1, demonstrating high affinity. 
Reference (2020, Anal Chim Acta ): Duffy, E., Florek, J., Colon, S., & Gerdon, A. E. (2020). Selected DNA aptamers as hydroxyapatite affinity reagents. Analytica Chimica Acta, 1110, 115–121. https://doi.org/10.1016/j.aca.2020.03.029
Aptamer: EP23
Target: Epithelial cellular adhesion molecule (EpCAM)
Type of nucleic acid: 2'-fluoro-RNA
Sequence: 5′ACGUAUCCCUUUUCGCGUA3′
Sequence length: 19
GC content: 0.4736842105263157
Affinity: Kd: 39.89 ± 3.37 nM
Pool type: 5’-GGGACACAATGGACG-N40-TAACGGCCGACATGAGAG-3’
Pool random region: 40
Binding buffer/conditions: PBS containing 5 mM MgCl2
Divalent salt: MgCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: For all of the aptamers, an amino-modifier-c6-tfa phosphoramidite group (6-[trifluoroacetylamino]hexyl-[(2-cyanoethyl)-(n,n-diisopropyl)]- phosphoramidite) and an inverted deoxythymidine group were added to the 5′- and 3′-end of the aptamers, respectively, for enhanced nuclease resistance. 
Application as quoted in the referenced paper: Therapeutic: " Study suggests that EP23 and the de novo designed aptamers primarily bind to EpCAM dimers (and not monomers, as hypothesized in previous published works), suggesting a paradigm for developing EpCAM-targeted therapies; this work confirms the utility of using in silico structure-based techniques to design and determine favorable RNA aptamers for physiological targets."
Additional information: #- This research article doesn't utilize a pool by experimenting with the in silico protocol. EP23 aptamer sequence includes the substitution (from 5' to 3') of 2′-fluoro for 2′-hydroxyl group in NTPs #2, 4, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 18.
Pool was found in:  Xiang D., et al., Superior performance of aptamer in tumor penetration over antibody: Implication of aptamer-based theranostics in solid tumors. Theranostics 5, 1083–1097 (2015). 
Aptamer sequence found in: Shigdar S., et al., RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci. 102, 991–998 (2011).
Reference (2020, Proc Natl Acad Sci U S A ): Bell, D. R., Weber, J. K., Yin, W., Huynh, T., Duan, W., & Zhou, R. (2020). In silico design and validation of high-affinity RNA aptamers targeting epithelial cellular adhesion molecule dimers. Proceedings of the National Academy of Sciences, 117(15), 8486–8493. https://doi.org/10.1073/pnas.1913242115
Aptamer: A5U
Target: Epithelial cellular adhesion molecule (EpCAM)
Type of nucleic acid: 2'-fluoro-RNA
Sequence: 5′ACGUUUCCCUUUUCGCGUA3′
Sequence length: 19
GC content: 0.4736842105263157
Affinity: Kd: 10.78 ± 1.37 nM
Pool type: Initial Sequence: ACGUAUCCCUUUUCGCGUA
Pool random region: 0
Binding buffer/conditions: PBS containing 5 mM MgCl3
Divalent salt: MgCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: For all of the aptamers, an amino-modifier-c6-tfa phosphoramidite group (6-[trifluoroacetylamino]hexyl-[(2-cyanoethyl)-(n,n-diisopropyl)]- phosphoramidite) and an inverted deoxythymidine group were added to the 5′- and 3′-end of the aptamers, respectively, for enhanced nuclease resistance. 
Application as quoted in the referenced paper: Therapeutic: " Study suggests that EP23 and the de novo designed aptamers primarily bind to EpCAM dimers (and not monomers, as hypothesized in previous published works), suggesting a paradigm for developing EpCAM-targeted therapies; this work confirms the utility of using in silico structure-based techniques to design and determine favorable RNA aptamers for physiological targets."
Additional information: #- This research article doesn't utilize a pool by experimenting with the in silico protocol. A5U aptamer sequence includes the substitution (from 5' to 3') of 2′-fluoro for 2′-hydroxyl group in NTPs #2, 4, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 18. An amino-modifier-C6-TFA phosphoramidite group (6-[trifluoroacetylamino]hexyl-[(2-cyanoethyl)-(N,N-diisopropyl)]- phosphoramidite) and an inverted deoxythymidine group were added to the 5′- and 3′-ends of the aptamer, respectively.
Reference (2020, Proc Natl Acad Sci U S A ): Bell, D. R., Weber, J. K., Yin, W., Huynh, T., Duan, W., & Zhou, R. (2020). In silico design and validation of high-affinity RNA aptamers targeting epithelial cellular adhesion molecule dimers. Proceedings of the National Academy of Sciences, 117(15), 8486–8493. https://doi.org/10.1073/pnas.1913242115
Aptamer: G15U
Target: Epithelial cellular adhesion molecule (EpCAM)
Type of nucleic acid: 2'-fluoro-RNA
Sequence: 5′ACGUAUCCCUUUUCUCGUA3′
Sequence length: 19
GC content: 0.4210526315789473
Affinity: Kd: 11.91 ± 0.95 nM
Pool type: Initial Sequence: ACGUAUCCCUUUUCGCGUA
Pool random region: 0
Binding buffer/conditions: PBS containing 5 mM MgCl4
Divalent salt: MgCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: For all of the aptamers, an amino-modifier-c6-tfa phosphoramidite group (6-[trifluoroacetylamino]hexyl-[(2-cyanoethyl)-(n,n-diisopropyl)]- phosphoramidite) and an inverted deoxythymidine group were added to the 5′- and 3′-end of the aptamers, respectively, for enhanced nuclease resistance. 
Application as quoted in the referenced paper: Therapeutic: " Study suggests that EP23 and the de novo designed aptamers primarily bind to EpCAM dimers (and not monomers, as hypothesized in previous published works), suggesting a paradigm for developing EpCAM-targeted therapies; this work confirms the utility of using in silico structure-based techniques to design and determine favorable RNA aptamers for physiological targets."
Additional information: #- This research article doesn't utilize a pool by experimenting with the in silico protocol. G15U aptamer sequence includes the substitution (from 5' to 3') of 2′-fluoro for 2′-hydroxyl group in NTPs #2, 4, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18. An amino-modifier-C6-TFA phosphoramidite group (6-[trifluoroacetylamino]hexyl-[(2-cyanoethyl)-(N,N-diisopropyl)]- phosphoramidite) and an inverted deoxythymidine group were added to the 5′- and 3′-ends of the aptamer, respectively.
Reference (2020, Proc Natl Acad Sci U S A ): Bell, D. R., Weber, J. K., Yin, W., Huynh, T., Duan, W., & Zhou, R. (2020). In silico design and validation of high-affinity RNA aptamers targeting epithelial cellular adhesion molecule dimers. Proceedings of the National Academy of Sciences, 117(15), 8486–8493. https://doi.org/10.1073/pnas.1913242115
Aptamer: CRP–Ugu4-3
Target: C-reactive protein (CRP). Human
Type of nucleic acid: 5-uracil-modified-DNA
Sequence: 5'GATATGTCCAGCCTGTCGAATGCCtAGttCtGCCttAAtAtGGtCGGttAAGCCTAAACTGATGTGCGGCGTAACC3'
Sequence length: 76
GC content: 0.4868421052631579
Affinity: Kd: 6.2 pM
Pool type: 5'-GATATGTCCAGCCTGTCGAATGC-N30-CTAAACTGATGTGCGGCGTAACC-3'
Pool random region: 30
Binding buffer/conditions: Selection buffer (SB; 40 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH7.5, 125 mM NaCl, 5 mM KCl, 1 mM MgCl2, 0.01% Tween 20)
Divalent salt: MgCl
Buffer type: Other Buffers
pH: 7.5
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Biosensor: " Human C-reactive protein (CRP) and lactate dehydrogenase are important markers in clinical laboratory testing-the former is used to detect in vivo inflammation, and the latter is used to detect cell necrosis and tissue destruction. We developed aptamers that bind to human CRP and human lactate dehydrogenase-5 (LDH-5). A potential application of these aptamers as sensor elements includes high-sensitivity target detection in point-of-care testing; These aptamers could be useful as biosensor elements with an electrochemical base of the target analyte."
Additional information: Used a modified DNA library containing the following base-appended base modifications: analog adenine derivative at the fifth position of uracil (Uad), analog guanine derivative at the fifth position of uracil (Ugu), and analog adenine derivative at the seventh position of adenine (Aad). *t indicates Ugu
Reference (2020, Int J Mol Sci ): Minagawa, H., Kataoka, Y., Fujita, H., Kuwahara, M., Horii, K., Shiratori, I., & Waga, I. (2020). Modified DNA Aptamers for C-Reactive Protein and Lactate Dehydrogenase-5 with Sub-Nanomolar Affinities. International Journal of Molecular Sciences, 21(8), 2683. https://doi.org/10.3390/ijms21082682